Table 1.
Participant demographics
| Participant cohort (n = 67) | |
|---|---|
| Male | 30 (44.8%) |
| Age (yrs) | 30 (25–41) |
| BNT162b2 Vaccine | 59 (88.1%) |
| CoronaVac Vaccine | 8 (11.9%) |
| No. of Days between 1st vaccination and 1st CMR Scan Examination (days) | 4 (1–8) |
| No. of Days between 2nd vaccination and 2nd CMR Scan Examination (days) | 4.7 2.4 |
| Days between 1st and 2nd Vaccine Dose (days) | 24 (21–28) |
| 1st Vaccination Injected into the Left Arm | 60 (89.6%) |
| 1st Vaccination Injected into the Right Arm | 5 (7.5%) |
| 1st Vaccination Injected into the Left Thigh | 2 (3.0%) |
| 2nd Vaccination Injected into the Left Arm | 60 (89.6%) |
| 2nd Vaccination Injected into the Right Arm | 5 (7.5%) |
| 2nd Vaccination Injected into the Left Thigh | 2 (3.0%) |
| Symptoms after 2nd COVID-19 Vaccination Dose | |
| Chest pain | 15 (22.4%) |
| Vomiting | 0 (0.0%) |
| Nausea | 4 (6.0%) |
| Pyrexia (≥ 38C) | 6 (9.0%) |
| Myalgia | 37 (55.2%) |
| Fatigue | 33 (49.3%) |
| Shortness of breath | 11 (16.4%) |
| Palpitations | 7 (10.4%) |
| Cardiac risk factors & Co-Morbidities | |
| Hypertension | 4 (6.0%) |
| Hyperlipidaemia | 4 (6.0%) |
| Obesity | 1 (1.5%) |
| Smoking | 3 (4.5%) |
| Diabetes Mellites Type 2 | 2 (3.0%) |
| Previous CABG | 0 (0.0%) |
| Previous coronary stent | 0 (0.0%) |
| Previous history of cancer | 0 (0.0%) |
| Drugs | |
| ACEI/ ARB | 1 (1.5%) |
| Beta-blockers | 2 (3.0%) |
| Calcium channel blockers | 2 (3.0%) |
| Diuretics | 0 (0.0%) |
| Clopidogrel | 0 (0.0%) |
| Aspirin | 1 (1.5%) |
| Anti-diabetic | 0 (0.0%) |
| Statin | 4 (6.0%) |
Variables are presented as number of participants and percentage in brackets for categorial data. For continuous variables, median with interquartile range or mean with standard deviation are displayed if the variables are normally distributed or not normally distributed